All News

2017

May

Media Release / May 18, 2017

Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care

Read More

March

Media Release / Mar 13, 2017

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Read More
2016

December

Media Release / Dec 09, 2016

Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole

Read More

November

Media Release / Nov 16, 2016

Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

Read More
Media Release / Nov 01, 2016

Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

Read More

October

Media Release / Oct 08, 2016

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

Read More

August

Media Release / Aug 03, 2016

Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer

Read More

May

Media Release / May 25, 2016

Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

Read More
Media Release / May 18, 2016

MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

Read More
2015

October

Media Release / Oct 27, 2015

Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More